Publication|Articles|November 14, 2025
Supplements and Featured Publications
- Economic Impact of Intravenous Versus Subcutaneous Administration of Infliximab on Health System Finances and Operations
Economic Impact of Intravenous Versus Subcutaneous Administration of Infliximab on Health System Finances and Operations
Advertisement
This clinical brief is supported by Celltrion Inc.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
TrumpRx Launch Brings Savings—and Uncertainty
2
As Cencora Closes With OneOncology, Patton Says Terms Show “Trust”
3
Benefits, Tradeoffs of Medically Integrated Dispensing in Oncology Care: Katherine Tobon, PharmD, BCOP
4
Asundexian Reduces Risk of Stroke Recurrence in Phase 3 OCEANIC-STROKE Trial
5
